Phase II trial of docetaxel and topotecan in recurrent and extensive small cell lung cancer

被引：0
|
作者：
Gormley, N
Edelman, MJ
Smith, R
Hausner, PF
Bedor, M
Bisaccia, S
机构：
[1] Univ Maryland, Greenebraum Canc Ctr, Baltimore, MD 21201 USA
[2] VA Maryland Hlth Care Syst, Baltimore, MD USA
来源：
LUNG CANCER | 2004年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S42 / S43
页数：2
相关论文
共 50 条
  • [41] A phase I/II trial of docetaxel and daily thalidomide in patients with previously treated recurrent non-small cell lung cancer.
    Seidler, CW
    Rooney, J
    Kodali, D
    Khanani, S
    Walsh, W
    Gordon, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 686S - 686S
  • [42] Phase II study with docetaxel in pretreated patients with small cell lung cancer
    Samantas, E
    Kiamouris, C
    Kalofonos, H
    Kourousis, H
    Aravantinos, G
    Janinis, J
    Androulakis, N
    Kourmpanis, V
    Fountzilas, G
    Skarlos, D
    ANNALS OF ONCOLOGY, 1998, 9 : 104 - 104
  • [43] A PHASE II STUDY OF AMRUBICIN AND TOPOTECAN COMBINATION THERAPY IN PATIENTS WITH RELAPSED OR EXTENSIVE-DISEASE SMALL-CELL LUNG CANCER: OKAYAMA LUNG CANCER STUDY GROUP TRIAL 0401
    Nogami, Naoyuki
    Kozuki, Toshiyuki
    Shinkai, Tetsu
    Katou, Yuka
    Hotta, Katsuyki
    Takigawa, Nagio
    Tabata, Masahiro
    Kiura, Katsuyuki
    Tanimoto, Mitsune
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S643 - S644
  • [44] A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401
    Nogami, Naoyuki
    Hotta, Katsuyuki
    Kuyama, Shoichi
    Kiura, Katsuyuki
    Takigawa, Nagio
    Chikamori, Kenichi
    Shibayama, Takuo
    Kishino, Daizo
    Hosokawa, Shinobu
    Tamaoki, Akihiko
    Harita, Shingo
    Tabata, Masahiro
    Ueoka, Hiroshi
    Shinkai, Tetsu
    Tanimoto, Mitsune
    LUNG CANCER, 2011, 74 (01) : 80 - 84
  • [45] Emerging role of weekly topotecan in recurrent small cell lung cancer
    Eckardt, JR
    ONCOLOGIST, 2004, 9 : 25 - 32
  • [46] Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Rubinsak, J. R.
    Spigel, D. R.
    Hainsworth, J. D.
    Webb, C.
    Inhorn, R. C.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Vazquez, E. R.
    Greco, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)
    Sovak, M. A.
    Lutzker, S.
    Guensch, L.
    Joyce, M.
    Schwartz, S.
    Wu, Y.
    Zheng, L.
    Aisner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] PHASE II TRIAL OF IMATINIB MESYLATE AND DOCETAXEL IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER
    Papadimitrakopoulou, Vassiliki
    Liu, Suyu
    Fujimoto, Junya
    Wistuba, Ignacio
    Lee, J. J.
    Marom, Edith M.
    Charnsangavej, Chusilp
    Fossella, Frank V.
    Tran, Hai T.
    Blumenschein, George
    Kies, Merrill
    Hong, Waun K.
    Stewart, David J.
    Tsao, Anne
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1235 - S1235
  • [49] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Valerie Israel
    Scott T. Tagawa
    Terry Snyder
    Susan Jeffers
    Derek Raghavan
    Investigational New Drugs, 2004, 22 : 291 - 297
  • [50] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Israel, V
    Tagawa, ST
    Snyder, T
    Jeffers, S
    Raghavan, D
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) : 291 - 297
12345